Waylis Therapeutics LLC

Privately held: no public share price

Assets

(4 total)
4Total Assets
4Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
GABA-A receptorSmall molecule
Epilepsy
Approved
Ribonucleotide reductaseSmall molecule
Sickle Cell Disease
Approved
Triglyceride metabolismSmall molecule
Severe Hypertriglyceridemia
Rabeprazole(Aciphex)
Approved
H+/K+-ATPase (gastric proton pump)Small molecule
Helicobacter pylori Infection

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.